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Abstract: Introduction: The potential of autologous matrix-induced chondrogenesis (AMIC) to
restore unipolar focal chondral defects of the knee is promising. However, the outcome compared to
microfracturing (MFx) for certain defect sizes (2–3 cm2) is still uncertain. Therefore, the present study
compared primary isolated AMIC versus MFx in a cohort of patients with borderline sized focal
unipolar chondral defects of the knee at midterm follow-up. Methods: Patients with chondral defects
of the knee who underwent AMIC or MFx were compared. An arthroscopic approach was used for
MFx, and a minimally invasive parapatellar arthrotomy for AMIC. For those patients who underwent
AMIC, a collagen membrane was used with fibrin glue. The patients answered independently: Visual
Analogic Scale (VAS), Tegner Activity Scale, International Knee Documentation Committee (IKDC),
and the Lysholm scores. Results: A total of 83 patients with a mean age of 30.2 and body mass
index (BMI) of 26.9 kg/m2 were recruited. Of them, 33.7% (28 of 83) were women, and 55.4% (46
of 83 patients) had defects in the right knee. The mean length of symptoms before surgery was
43.3 months. The mean size of the defect was 2.7 cm2. The mean length of follow-up was 42.1 months.
No difference was found in terms of symptoms and follow-up length, mean age and BMI, mean size
of defect, sex, and side. The AMIC cohort reported greater IKCD (p > 0.0001), Lysholm (p = 0.002),
VAS (p = 0.01), Tegner (p = 0.004) scores. The AMIC cohort reported lower rate of failure (p = 0.005)
and revision surgery (p = 0.02). No difference was found in the rate of arthroplasty (p = 0.2). No
delamination or hypertrophy were detected. Conclusion: AMIC demonstrated superiority over
MFx for focal unipolar chondral defects of the knee. At approximately 40 months follow-up, the
IKDC, Lysholm, and VAS scores were greater in the AMIC group. Patients treated with AMIC also
demonstrated a higher level of sport activity, and lower rates of failure and revision surgeries.
Keywords: autologous matrix-induced chondrogenesis (AMIC); chondral defects; knee
1. Introduction
Focal chondral defects of the knee are common and are detected in up to 72% of
patients undergoing knee arthroscopy [1,2]. Symptomatic chondral defects impair the
quality of life and sporting activity level of the affected patients [3,4]. The alymphatic
and hypocellular hyaline cartilage along with its low metabolic activity account for its
poor regenerative capabilities [5–7]. Acute chondral injuries usually do not result in a
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restitutio ad integrum, rather in the production of fibrocartilage, and residual chondral
defects are common [8,9]. Treating these patients is challenging and controversial [10,11].
Generally, isolated microfractures (MFx) have been proposed for chondral defects up to
2.5 cm2 [11–15]. For larger defects, several surgical strategies are available. Osteochondral
allograft and/or autograft transplantation (OAT) and autologous chondrocyte implantation
(ACI) have been widely performed in bigger defects [16–18]. However, the need of a har-
vesting site, two stage surgeries, or cell culture and expansion, have encouraged researchers
to develop less labour-intensive strategies [19–21]. To overcome these problems, in 2005,
Behrens et al. [22] firstly described an enhanced microfractures technique, which developed
into the autologous matrix-induced chondrogenesis (AMIC) procedure. AMIC does not
necessitate harvesting any autologous tissue to extract and expand chondrocytes [4,23].
Moreover, AMIC is performed in a single-session surgery, exploiting the potential of bone
marrow-derived mesenchymal stem cells (BM-MSCs) [24,25]. Thus, AMIC quickly gained
ground in the field of cartilage defect regeneration [26].
To the best of our knowledge, only three studies have compared AMIC versus MFx in
knee with chondral defects [27–29]. However, no previous study has analysed the outcome
of tibio- and patellofemoral lesions in a separate fashion, nor have primary procedures and
revision settings been considered separately. Furthermore, the indications for borderline
sized defects (2.2 to 2.8 cm2) are debated. The present study compared primary isolated
AMIC versus MFx in a cohort of patients with focal chondral defects of the femorotibial
joint of the knee at midterm follow-up.
2. Material and Methods
2.1. Study Design
The present study was performed according to the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) [30]. This study was conducted in the
Department of Orthopaedic Surgery of the University Hospital RWTH Aachen, Germany,
between 2012 and 2020. Patients undergoing primary isolated AMIC or MFx for borderline
sized unipolar focal chondral defects of the knee were examined, and their suitability
to participate in this study was evaluated. The inclusion criteria were (1) symptomatic
chondral defect, (2) single focal defect sized 2 to 3 cm2, (3) magnetic resonance imaging
(MRI) evidence (Figure 1), (4) being able to understand the nature of the treatment and
the study. The exclusion criteria were (1) kissing lesions, (2) bilateral lesions, (3) multiple
lesions, (4) previous knee surgery, (5) any bone disease, (6) varus or valgus deformity,
(7) grade II to IV according to the Kellgren and Lawrence grading system [31]. In case of
suspected varus/valgus axial deformities, we obtained plain weightbearing radiographies
to evaluate the Q-angle. Suitable patients received information about pros and cons of both
techniques, and if they consented to participate in this study, they were free to decide their
own treatment. Finally, in 2020, patients were invited to participate in our investigation.
The present study was approved and registered by the ethics committee of the RWTH
University of Aachen (project ID EK 438-20) and conducted according to the principles
expressed in the Declaration of Helsinki. All patients were able to understand the nature
of their treatment and provided written consent to use their clinical and imaging data for
research purposes.
2.2. Surgical Technique
All the surgeries were performed in the same fashion by two experienced surgeons (B.R.
and M.T.) according to a previous report [32]. Briefly, preliminary diagnostic arthroscopy
was performed through standard anteromedial and anterolateral portals. After debride-
ment of the chondral defect to achieve stable cartilage borders, we performed microfrac-
tures of 4 mm depth in a full-arthroscopic fashion. For those patients who underwent
AMIC, a minimally invasive parapatellar arthrotomy was performed. Debridement and
curettage of the non-viable tissues surrounding the lesion was then performed. In cases of
subchondral bone defect (e.g., osteochondral defect, osteochondritis dissecans), non-vital
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bone was removed, and the defect was filled with autologous cancellous bone graft har-
vested from the ipsilateral iliac crest. A type I/III resorbable collagen membrane (from
2012 to 2016: Chondro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland; from 2016 to
2020: Cartimaix, Matricel, Herzogenrath, Germany) was trimmed to slightly undersize the
defect to avoid displacement. The membrane was hydrated in a saline solution and placed
into the lesion. Fibrin glue was used to secure the membrane into the defect. The stability
of the membrane was checked by repeatedly flexing and extending the knee under direct
vision. Irrespective to the treatment allocation, patients received the same post-operative
rehabilitation. Continuous passive motion up to 90◦ on the operated knee started 12 h after
surgery to minimise the risk of intra-articular adhesions, along with isometric contractions
of the quadriceps and active flexion of the ankle to encourage lower extremity circulation.
For the first 6 post-operative weeks, patient ambulation was allowed, with maximal 15 kg
of weightbearing using 2 elbow crutches. Over the following 2 weeks, only half body
weightbearing was allowed. Starting from 10 weeks, full weightbearing was allowed.




Figure 1. MRI sequences of a focal chondral defect of the medial femoral condyle in a 28-year-old male patient: axial (a) 
and sagittal (b) views using a proton density turbo spin-echo SPIR sequence; sagittal (c) and coronal (e) views of T1-
weighted SPIR sequence; coronal view of proton density turbo spin-echo (f) and with SPIR sequence (d). 
2.2. Surgical Technique 
All the surgeries were performed in the same fashion by two experienced surgeons 
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debridement of the chondral defect to achieve stable cartilage borders, we performed mi-
crofractures of 4 mm depth in a full-arthroscopic fashion. For those patients who under-
went AMIC, a minimally invasive parapatellar arthrotomy was performed. Debridement 
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cases of subchondral bone defect (e.g., osteochondral defect, osteochondritis dissecans), 
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graft harvested from the ipsilateral iliac crest. A type I/III resorbable collagen membrane 
(from 2012 to 2016: Chondro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland; from 
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.3. Outcomes of Inter st
On admission, age, gender, side, area of defect, additional autologous cancell u
bone grafting, body mass index (BMI), sym tom duration prior to surgery, and length of
hospital stay were recor ed. Following w itte informed co sent, the patients performed
the followi g scor s: Visual Analogic Scale (VAS), Tegne Activity Scale International Knee
D cumentation Committee (IKDC), and the Lysholm scores. The M gnetic Resonance
Observation of Cartil ge Rep ir Tissue (MOCART) sc re was assigned by a blinded radiol-
ogist not involved in the clinical management. Data concerning the rate of complications
(failure, revisi , arthroplasty, delamination, hypertrophy) and additional proc dures
were also collected. Failure was defined as persistent pain that negatively affected th
quality of life and limited articipation to recreational activities. A subgroup analysis was
performed to investigate differences between patients receiving cancellous bone grafting
and those undergoing an isolated chondral procedure. A further subgroup analysis was
Life 2021, 11, 183 4 of 10
conducted to investigate whether the 2 membranes (Chondro-Gide, Cartimaix) provided
different outcomes.
2.4. Statistical Analysis
All statistical analyses were performed using the software IBM SPSS version 25.
Continuous data were analysed using the mean difference (MD), while for dichotomic data,
the odds ratio (OR) effect measures were calculated. The confidence interval was set at




A total of 124 patients were initially screened. Of them, 33 were not eligible due to
kissing lesions (N = 3), bilateral lesions (N = 1), multiple lesions (N = 5), previous knee
surgeries (N = 21), bone disease (N = 1), or skeletal malformation or deformity (N = 2).
A total of 91 patients were available and operated: 56 AMIC and 35 microfractures. At
the last follow-up, four patients in the AMIC group and four in the microfractures group
were not available. The eight patients who did not attend the last follow-up were contacted
telephonically and declared themselves satisfied but unavailable to attend assessment
for geographical reasons. Eventually, 83 patients were enrolled in the present study:
52 underwent AMIC, and 31 MFx (Figure 2).




Figure 2. Diagram of the recruitment process. 
3.2. Patient Demographics 
We analysed data from the 83 patients who completed the study. Of them, 33.7% (28 
of 83) were women, and in 55.4% (46 of 83 defects) the lesion was located on the right side. 
The mean age was 30.2, and the mean BMI was 26.9 kg/m2. The mean duration of symp-
toms before surgery was 43.3 months. The mean size of the defect was 2.7 cm2 (1.9 to 3.1). 
The mean length of the follow-up was 42.1 months. The MFx group had a shorter duration 
of the hospitalisation compared to the AMIC cohort (p = 0.03). No difference was found in 
terms of symptoms and follow-up length, mean age and BMI, mean size of defect, sex, 
and side (Table 1). 
Table 1. Demographic data of the patients (n.s.: not significant). 
Endpoint AMIC (n = 52) MFx (n = 31) p 
Follow-up (months) 43.7 ± 27.6 39.5 ± 19.1 n.s.  
Age 29.5 ± 12.1 31.3 ± 9.9 n.s. 
Gender (female) 34.6%  32.3%  n.s. 
Side (right leg) 55.8%  54.8%  n.s. 
Side (knee compartment)    
Lateral  35%  42%  n.s. 
Medial 65%  58%  n.s. 
Spongiosa transplantation 32.7%  -  
Membrane    
Figure 2. Diagram of the recruitment process.
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3.2. Patient Demographics
We analysed data from the 83 patients who completed the study. Of them, 33.7% (28
of 83) were women, and in 55.4% (46 of 83 defects) the lesion was located on the right
side. The mean age was 30.2, and the mean BMI was 26.9 kg/m2. The mean duration of
symptoms before surgery was 43.3 months. The mean size of the defect was 2.7 cm2 (1.9
to 3.1). The mean length of the follow-up was 42.1 months. The MFx group had a shorter
duration of the hospitalisation compared to the AMIC cohort (p = 0.03). No difference was
found in terms of symptoms and follow-up length, mean age and BMI, mean size of defect,
sex, and side (Table 1).
Table 1. Demographic data of the patients (n.s.: not significant).
Endpoint AMIC (n = 52) MFx (n = 31) p
Follow-up (months) 43.7 ± 27.6 39.5 ± 19.1 n.s.
Age 29.5 ± 12.1 31.3 ± 9.9 n.s.
Gender (female) 34.6% 32.3% n.s.
Side (right leg) 55.8% 54.8% n.s.
Side (knee compartment)
Lateral 35% 42% n.s.
Medial 65% 58% n.s.




Symptom duration (months) 48.1 ± 80.7 35.3 ± 66.8 n.s.
Length of hospital stay (days) 4.5 ± 1.6 3.1 ± 0.9 0.03
Area of defect (cm2) 2.8 ± 2.5 2.6 ± 1.8 n.s.
BMI (kg/m2) 27.1 ± 4.4 26.5 ± 3.9 n.s.
Compartment
Lateral compartment 34.6% 29.0% n.s.
Medial compartment 65.4% 71.0%% n.s.
3.3. Outcomes of Interest
The AMIC cohort reported greater IKCD (p = 0.007), Lysholm (p = 0.02), VAS (p = 0.008),
and Tegner (p < 0.0001), while the MOCART score was similar (p = 0.7) (Table 2).
Table 2. Results of scores.
Endpoint AMIC (n = 52) MFx (n = 31) 95% CI MD p
IKCD 75.9 ± 24.6 63.3 ± 6.3 3.619, 1.581 12.6 0.007
Lysholm 71.2 ± 24.3 59.9 ± 12.5 1.942, 20.658 11.3 0.02
MOCART 70.0 ± 19.4 68.4 ± 14.3 −6.384, 9.584 1.6 0.7
VAS (0–10) 2.5 ± 2.1 4.1 ± 3.3 0.422, 2.778 1.6 0.008
Tegner 4.8 ± 1.5 3.1 ± 0.9 1.108, 2.292 1.7 <0.0001
3.4. Complications
The AMIC cohort reported lower rate of failure (p = 0.005) and revision surgery
(p = 0.02). No difference was found in the rate of conversion to arthroplasty during the du-
ration of the follow-up (p = 0.2). No delamination or hypertrophy were detected (Table 3).
Table 3. Complications.
Endpoint AMIC (n = 52) MFx (n = 31) 95% CI OR p
Failure 3.8% 29.0% 0.0195, 0.4902 0.098 0.005
Knee
arthroplasty 0 6.5% 0.0054, 2.5005 0.116 0.2
Revision surgery 1.9% 19.4% 0.0093, 0.7159 0.082 0.02
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3.5. Subgroup Analysis
No statistically significant difference was found in term of PROMs and complications
between the AMIC subgroup that received cancellous bone grafting compared to those that
received only the chondral procedure, and between those that received the Chondro-Gide
and the Cartimaix membranes.
4. Discussion
The main finding of the present study was that AMIC demonstrated superiority over
MFx for focal unipolar chondral defects of the knee of an average area of 2.7 cm2. At
approximately 40 months follow-up, IKDC, Lysholm, and VAS were greater in the AMIC
group. Patients treated with AMIC also demonstrated a higher level of sporting activity,
along with lower rates of failure and revision surgery. The MOCART score detected no
morphological difference in the cartilage at final follow-up. Similarity was found between
patients who received cancellous bone grafting compared to those who received only
the chondral procedure, and between those who received the Chondro-Gide and the
Cartimaix membranes.
For chondral defect of the knee up to 2.5 cm2, MFx is indicated [11–15], and AMIC
has been proposed for larger defects [4,23–25]. The patients included in the present study
presented a mean defect area of 2.7cm2, slightly larger than what classically considered as
the upper limit for MFx. The treatment of patients with borderline defect size is debated.
Given its rapidity, the avoidance of arthrotomy, and the quick recovery time, MFx is often
preferred in patients with borderline defect sizes. However, our results demonstrated
that for borderline lesions, AMIC provided better outcomes, justifying the procedure. We
were able to identify three studies that compared AMIC versus MFx for knee chondral
defects [27–29]. Chung et al. [29] compared AMIC versus MFx on 64 patients. Although the
overall values of IKDC and VAS were significantly better in the AMIC group at two years
follow-up, the differences were not statistically significant. However, they performed the
surgeries in a cohort of patients with a mean defect size of 1.3 cm2 in the AMIC group and
1.5 cm2 in the MFx group. For these sizes, MFx is still believed to be the most appropriate
indications [5–7,14]. Volz et al. [27], in a prospective multicentre clinical trial, compared
AMIC versus MFx on 47 patients. Similarly, they found a significant greater value of
Cincinnati score and lower pain level in the AMIC cohort with an average size of the
defects 3.6 cm2. However, differently to us, the MRI findings were significantly better in the
AMIC group. They further compared glued versus sutured AMIC membrane—the glued
membrane performed better than the sutured. Indeed, although suturing allows for greater
membrane stability, it produces partial thickness lesions of the cartilage. These lesions may
not heal, and may enlarge over the time [33,34]. Hunzinker et al. [35] demonstrated severe
tissue impairment of the peri-suture area, which may lead to pain, reduced healing, and
premature osteoarthritis [35]. It is unclear whether to use glue or no fixation. However,
we believe that glue did not interfere negatively with cartilage regeneration and can be
safely employed during AMIC. Similarly, Anders et al. [28] performed a comparative study
between glued AMIC, sutured AMIC, and isolated MFx. The modified Cincinnati and
ICRS scores were comparable between the three groups at two-year follow-up, as were the
MRI findings. Regarding complications, while Anders et al. [28] reported no complications,
Volz et al. [27] reported one total knee arthroplasty in the AMIC group and one revision in
the MFx cohort. These results are in contrast to our findings, which reported significant
lower rates of failure and revision surgery in the AMIC group. We hypothesise that the
reason of this discrepancies arises from the longer follow-up of the present study (42.1 vs.
24 months).
De Girolamo et al. [23] performed enhanced AMIC with bone marrow aspirate con-
centrate (BMAC) harvested form the ipsilateral iliac crest on 24 patients. They found
comparability between AMIC and the enhanced technique at 9 years follow-up. How-
ever, given the faster recovery in the enhanced cohort, they recommended this procedure
on patients who require faster return to sports [23]. In a similar setting involving nine
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patients, Enea et al. [36] found that BMAC-enhanced AMIC is safe and provides good
clinical outcomes at 22 months follow-up. Additionally, they performed a second-look
arthroscopy on five patients. This demonstrated a normal cartilage in one patient, nearly
normal cartilage in three patients, and abnormal healing in one patient [36]. They further
performed a biopsy in two patients, evidencing hyaline-like tissue, rich in proteoglycans
and chondrocytes [36]. Given the simple and quick execution, enhanced AMIC may prove
interesting for the management of chondral defects, and further investigations are required.
Currently, there is a growing interest in new strategies for regeneration of chondral
defects. Pipino et al. reported their preliminary results of MFx enhanced with the hydrogel
polyglucosamine/glucosamine carbonate (PG/GC) in a clinical setting [37]. The Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score of their patients
improved of 88% at 6 months and 95% at 24 months [37]. Several other synthetic scaffolds
have been proposed for MFx augmentation. Synthetic polymers, such as polyglycolic acid
(PGA), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), and polyethylene glycol-
terephthalate/polybutylene terephthalate (PEOT/PBT), have been investigated [38–40].
However, evidence is lacking and their use is still debated [41,42].
Patients presenting non-vital subchondral bone who received AMIC combined with
cancellous bone grafting showed similar results compared to those who underwent the
isolated chondral procedure. The cancellous bone used for the graft was harvested from the
ipsilateral iliac crest. Given its osteogenic and neoangiogenic potential, iliac crest cancellous
bone graft is rapidly incorporated into the host site [43,44]. However, the limited number
of samples included for analysis may have influenced the results. Similar limitations can
be inferred with regards to the comparison between the Chondro-Gide and Cartimaix
membranes. Patients did not consent to be randomly allocated or blinded, representing an
important limitation. The morphological quality assessment of regeneration was evaluated
through the MOCART score, which evidenced no differences between the two techniques.
Whether the morphological appearance at MRI is reliable in predicting clinical outcome
after cartilage repair is questionable. The MRI classification demonstrates no correlation
with clinical outcomes after cartilage repair surgery [45–47]. Older age is a negative prog-
nostic factor for the success of chondral procedures [48–50]. The AMIC cohort was slightly
younger than the MFx group. Although this difference was not statistically significant,
we cannot estimate whether this may have affected our results. The limited number of
the included patients jeopardises the capability to investigate uncommon complications.
Longer follow-up is required to establish long-term complications and morphological
changes in the quality of regenerated cartilage.
5. Conclusions
AMIC demonstrated superiority over MFx for focal unipolar chondral defects of the
femorotibial joint of the knee. At approximately 40 months follow-up, IKDC, Lysholm, and
VAS were greater in the AMIC group. Patients treated with AMIC also demonstrated a
higher level of sporting activity, along with lower rates of failure and revision surgery.
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